Tofacitinib for the treatment of psoriasis

Expert Opinion on Pharmacotherapy

Volumn 17, Issue 10, 2016, Pages 1421-1433

  Galluzzo, M ^a   D'Adamio S ^a   Servoli, S ^a   Bianchi, L ^a   Chimenti, S ^a   Talamonti, M ^a  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

Author keywords

cytokines; JAK STAT pathway; phase III trial; psoriasis; Small molecule drugs; Th17

Indexed keywords

ADENOSINE TRIPHOSPHATE; CYTOKINE RECEPTOR; INTERFERON; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 13; INTERLEUKIN 15; INTERLEUKIN 19; INTERLEUKIN 2; INTERLEUKIN 20; INTERLEUKIN 21; INTERLEUKIN 22; INTERLEUKIN 23; INTERLEUKIN 23 RECEPTOR; INTERLEUKIN 24; INTERLEUKIN 26; INTERLEUKIN 27; INTERLEUKIN 35; INTERLEUKIN 4; INTERLEUKIN 6; INTERLEUKIN 7; INTERLEUKIN 9; JANUS KINASE; JANUS KINASE INHIBITOR; STAT PROTEIN; STAT1 PROTEIN; STAT3 PROTEIN; TOFACITINIB; BIOLOGICAL MARKER; PIPERIDINE DERIVATIVE; PROTEIN KINASE INHIBITOR; PYRIMIDINE DERIVATIVE; PYRROLE DERIVATIVE;

ARTICLE; BINDING SITE; CARDIOVASCULAR RISK; CLINICAL PRACTICE; COMORBIDITY; CYTOKINE PRODUCTION; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; ENZYME INACTIVATION; FOOD AND DRUG ADMINISTRATION; HISTOLOGY; HUMAN; LYMPHOCYTIC INFILTRATION; NATURAL KILLER CELL; OBESITY; PATHOGENESIS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PSORIASIS; SKIN BIOPSY; TREATMENT RESPONSE; DRUG ADMINISTRATION; METABOLISM;

BIOMARKERS; DRUG ADMINISTRATION SCHEDULE; HUMANS; PIPERIDINES; PROTEIN KINASE INHIBITORS; PSORIASIS; PYRIMIDINES; PYRROLES;

EID: 84975291673     PISSN: 14656566     EISSN: 17447666     Source Type: Journal    
DOI: 10.1080/14656566.2016.1195812     Document Type: Article

References (100)

1. R.Parisi, D.P.Symmons, C.E.Griffiths, et al. Global epidemiology of psoriasis: a systematic review of incidence and prevalence. J Invest Dermatol. 2013;133:377–385.
2. Y.-W.Yang, J.J.Keller, H.-C.Lin Medical comorbidity associated with psoriasis in adults: a population-based study. Br J Dermatol. 2011;165(5):1037–1043.
3. L.Puig. PASI90 response: the new standard in therapeutic efficacy for psoriasis. J Eur Acad Dermatol Venereol. 2015;29(4):645–648.
4. C.E.Griffiths, J.N.Barker. Pathogenesis and clinical features of psoriasis. Lancet. 2007;370(9583):263–271.
5. L.C.Tsoi, S.L.Spain, E.Ellinghaus, et al. Enhanced meta-analysis and replication studies identify five new psoriasis susceptibility loci. Nat Commun. 2015;6:7001.
6. X.Yin, H.Q.Low, L.Wang, et al. Genome-wide meta-analysis identifies multiple novel associations and ethnic heterogeneity of psoriasis susceptibility. Nat Commun. 2015;6:6916.
7. V.Chandran. The genetics of psoriasis and psoriatic arthritis. Clin Rev Allergy Immunol. 2013;44(2):149–156.
8. A.Menter, A.Gottlieb, S.R.Feldman, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. J Am Acad Dermatol. 2008;58(5):826–850.
9. C.Albanesi, O.De Pita, G.Girolomoni. Resident skin cells in psoriasis: a special look at the pathogenetic functions of keratinocytes. Clin Dermatol. 2007;25:581–588.
10. G.Girolomoni, U.Mrowietz, C.Paul. Psoriasis: rationale for targeting interleukin-17. Br J Dermatol. 2012;167(4):717–724.
11. C.Lynde, Y.Poulin, R.Vender, et al. Interleukin 17A: toward a new understanding of psoriasis pathogenesis. J Am Acad Dermatol. 2014;71:141–150.•• Discussion on the rationale for targeting IL-17 in psoriasis.
12. M.Lowes, C.Russell, D.Martin, et al. The IL-23/T17 pathogenic axis in psoriasis is amplified by keratinocyte responses. Trends Immunol. 2013;34(4):174–181.
13. S.L.Gaffen. Structure and signalling in the IL-17 receptor family. Nat Rev Immunol. 2009;9:556–567.
14. A.Laurence, K.Ghoreschi, K.Hirahara, et al. Therapeutic inhibition of the Janus kinases. Inflamm Regen. 2012;32:16–22.
15. J.J.O’shea. Targeting the Jak/STAT pathway for immunosuppression. Ann Rheum Dis. 2004;63(Suppl II):ii67–ii71.
16. T.Vaidya, S.R.Feldman, J.Kirk. Patient-centered approach to biologics in the treatment of psoriasis. J Nat Sci. 2015;1(3):e53.
17. A.A.Levin, A.B.Gottlieb, S.C.Au. A comparison of psoriasis drug failure rates and reasons for discontinuation in biologics vs. conventional systemic therapies. J Drugs Dermatol. 2014;13(7):848–853.
18. E.Christophers, S.Segaert, G.Milligan, et al. Clinical improvement and satisfaction with biologic therapy in patients with severe plaque psoriasis: results of a European cross-sectional observational study. J Dermatolog Treat. 2013;24(3):193–198. doi:10.3109/09546634.2012.697112.
19. R.B.Warren, C.E.M.Griffiths. The future of biological therapies. Semin Cutan Med Surg. 2010;29:63–66.
20. H.Yeung, J.Wan, A.S.Van Voorhees, et al. Patient-reported reasons for the discontinuation of commonly used treatments for moderate to severe psoriasis. J Am Acad Dermatol. 2013;68(1):64–72. doi:10.1016/j.jaad.2012.06.035.
21. R.Gniadecki, K.Kragballe, T.N.Dam, et al. Comparison of drug survival rates for adalimumab, etanercept and infliximab in patients with psoriasis vulgaris. Br J Dermatol. 2011;164(5):1091–1096. doi:10.1111/j.1365-2133.2011.10213.x.
22. A.M.Brunasso, M.Puntoni, C.Salvini, et al. Tolerability and safety of biological therapies for psoriasis in daily clinical practice: a study of 103 Italian patients. Acta Derm Venereol. 2011;91(1):44–49. doi:10.2340/00015555-0959.
23. K.Ortiz-Ibáñez, M.M.Alsina, C.Muñoz-Santos. Tofacitinib and other kinase inhibitors in the treatment of psoriasis. Actas Dermosifiliogr. 2013;104(4):304–310.
24. R.B.Hansen, A.Kavanaugh. Novel treatments with small molecules in psoriatic arthritis. Curr Rheumatol Rep. 2014;16(9):443.
25. K.Kofoed, L.Skov, C.Zachariae. New drugs and treatment targets in psoriasis. Acta Derm Venereol. 2015 Feb;95(2):133–139.
26. P.J.Murray. The JAK-STAT signaling pathway: input and output integration. J Immunol. 2007;178(5):2623–2629.•• Detailed description of the molecular mechanism of JAK/STAT signaling pathway.
27. J.S.Rawlings, K.M.Rosler, D.A.Harrison. The JAK/STAT signaling pathway. J Cell Sci. 2004;117(8):1281–1283.
28. K.Ghoreschi, A.Laurence, J.J.O’Shea. Janus kinases in immune cell signaling. Immunol Rev. 2009;228(1):273–287.
29. D.-Q.Li, Z.Chen, X.J.Song, et al. Stimulation of matrix metalloproteinases by hyperosmolarity via a JNK pathway in human corneal epithelial cells. Invest Ophthalmol Visual Sci. 2004;45(12):4302–4311.
30. D.M.Meyer, M.I.Jesson, X.Li, et al. Anti-inflammatory activity and neutrophil reductions mediated by the JAK1/JAK3 inhibitor, CP-690,550, in rat adjuvant-induced arthritis. J Inflamm. 2010;7(41):1–12.
31. L.A.O’Sullivan, C.Liongue, R.S.Lewis, et al. Cytokine receptor signaling through the Jak-Stat-Socs pathway in disease. Mol Immunol. 2007;44(10):2497–2506.
32. M.Pesu, A.Laurence, N.Kishore, et al. Therapeutic targeting of Janus kinases. Immunol Rev. 2008;223(1):132–142.
33. J.G.Walker, M.J.Ahern, M.Coleman, et al. Characterization of a dendritic cell subset in synovial tissue which strongly expresses Jak/STAT transcription factors from patients with rheumatoid arthritis. Ann Rheum Dis. 2007;66:992–999.
34. C.Chen, X.Zhang, Y.Wang. Analysis of JAK2 and STAT3 polymorphisms in patients with ankylosing spondylitisin Chinese Han population. Clin Immunol. 2010;136:442–446.
35. C.A.Anderson, D.C.O.Massey, J.C.Barrett, et al. Investigation of Crohn’s disease risk loci in Ulcerative colitis further defines their molecular relationship. Gastroenterology. 2009;136:523–529.
36. E.F.Remmers, R.M.Plenge, A.T.Lee, et al. STAT4 and the risk of rheumatoid arthritis and systemic lupus erythematosus. N Engl J Med. 2007 Sep 6;357(10):977–986.
37. K.Wolk, E.Witte, E.Wallace, et al. IL-22 regulates the expression of genes responsible for antimicrobial defense, cellular differentiation, and mobility in keratinocytes: a potential role in psoriasis. Eur J Immunol. 2006 May;36(5):1309–1323.
38. Y.Zheng, D.M.Danilenko, P.Valdez, et al. Interleukin-22, a T(H)17 cytokine, mediates IL-23-induced dermal inflammation and acanthosis. Nature. 2007 Feb 8;445(7128):648–651.
39. X.Zhou, J.G.Krueger, M.C.Kao, et al. Novel mechanisms of T-cell and dendritic cell activation revealed by profiling of psoriasis on the 63,100-element oligonucleotide array. Physiol Genomics. 2003 Mar 18;13(1):69–78.
40. L.Van Der Fits, L.I.Van Der Wel, J.D.Laman, et al. In psoriasis lesional skin the type I interferon signaling pathway is activated, whereas interferon-alpha sensitivity is unaltered. J Invest Dermatol. 2004 Jan;122(1):51–60.
41. Y.Zhang, Y.Zhang, W.Gu, et al. TH1/TH2 cell differentiation and molecular signals. Adv Exp Med Biol. 2014;841:15–44.
42. K.Nakajima. Critical role of the interleukin-23/T-helper 17 cell axis in the pathogenesis of psoriasis. J Dermatol. 2012 Mar;39(3):219–224.
43. K.Ghoreschi, M.I.Jesson, X.Li, et al. Modulation of innate and adaptive immune responses by tofacitinib (CP-690,550). J Immunol. 2011;186(7):4234–4243.•• Extended report of the mode of action of tofacitinib on JAK/STAT signaling.
44. M.W.Karaman, S.Herrgard, D.K.Treiber, et al. A quantitative analysis of kinase inhibitor selectivity. Nat Biotechnol. 2008;26(1):127–132.
45. P.S.Changelian, M.E.Flanagan, D.J.Ball, et al. Prevention of organ allograft rejection by a specific Janus kinase 3 inhibitor. Science. 2003;302(5646):875–878.
46. E.Kudlacz, B.Perry, P.Sawyer, et al. The novel JAK-3 inhibitor CP-690550 is a potent immunosuppressive agent in various murine models. Am J Transplant. 2004;4(1):51–57.
47. A.J.Milici, E.M.Kudlacz, L.Audoly, et al. Cartilage preservation by inhibition of Janus kinase 3 in two rodent models of rheumatoid arthritis. Arthritis Res Ther. 2008;10(1):R14.
48. M.G.Boy, C.Wang, B.E.Wilkinson, et al. Double-blind, placebo-controlled, dose-escalation study to evaluate the pharmacologic effect of CP-690,550 in patients with psoriasis. J Invest Dermatol. 2009;129(9):2299–2302.•• The first phase I study with published results on oral tofacitinib for the treatment of plaque-type psoriasis.
49. R.Fleischmann, M.Cutolo, M.C.Genovese, et al. Phase 2B dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) or adalimumab monotherapy versus placebo in patients with active rheumatoid arthritis with an inadequate response to DMARDs. Arthritis Rheum. 2012;64(3):617–629.
50. Y.Tanaka, M.Suzuki, H.Nakamura, et al. Phase II study of tofacitinib (CP-690,550) combined with methotrexate in patients with rheumatoid arthritis and an inadequate response to methotrexate. Arthritis Care Res. 2011;63(8):1150–1158.
51. D.Wojciechowski, F.Vincenti. Targeting JAK3 in kidney transplantation: current status and future options. Curr Opin Organ Transplant. 2011;16(6):614–619.
52. J.Wollenhaupt, J.C.Silverfield, E.B.Lee, et al. Tofacitinib (CP-690,550), an oral Janus kinase inhibitor, in the treatment of rheumatoid arthritis: open label, long-term extension studies up to 36 months. Arthritis Rheum. 2011;63(10Suppl.):161–162.
53. J.Kremer, Z.-G.Li, S.Hall, et al. Tofacitinib (CP-690,550), an oral JAK inhibitor, in combination with traditional DMARDS: phase 3 study in patients with active rheumatoid arthritis with inadequate response to DMARDs. Ann Rheum Dis. 2011;70(Suppl. 3):170.
54. J.M.Kremer, S.Cohen, B.E.Wilkinson, et al. A phase 2B dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) versus placebo in combination with background methotrexate in patients with active rheumatoid arthritis and inadequate response to methotrexate alone. Arthritis Rheum. 2012;64(4):970–981.
55. Van Der Heijde D, Tanaka Y, Fleischmann R, et al. Tofacitinib (CP-690,550) in patients with rheumatoid arthritis receiving methotrexate: twelve-month data from a twenty-four-month phase III randomized radiographic study. Arthritis Rheum. 2013;65(3):559–570.
56. B.R.Burmester Gerd-Reudiger, C.Charles-Schoeman, J.Wollenhaupt, et al. Tofacitinib (CP-690,550), an oral Janus kinase inhibitor, in combination with methotrexate, in patients with active rheumatoid arthritis with an inadequate response to tumor necrosis factor inhibitors: a 6-month phase 3 study. Arthritis Rheum. 2011;63(10 Suppl.):288.
57. K.Kaur, S.Kalra, S.Kaushal. Systematic review of tofacitinib: a new drug for the management of rheumatoid arthritis. Clin Ther. 2014;36(7):1074–1086.
58. D.J.Cada, K.Demaris, T.L.Levien, et al. Tofacitinib. Hosp Pharm. 2013;48(5):413–424.
59. L.Hsu, A.W.Armstrong. JAK inhibitors: treatment efficacy and safety profile in patients with psoriasis. J Immunol Res. 2014;2014:283617.
60. E.Y.Gan, W.S.Chong, H.L.Tey. Therapeutic strategies in psoriasis patients with psoriatic arthritis: focus on new agents. Bio Drugs. 2013;27(4):359–373.
61. Pfizer. Available from: www.pfizer.com/pipeline.
62. M.E.Dowty, J.Lin, T.F.Ryder, et al. The pharmacokinetics, metabolism, and clearance mechanisms of tofacitinib, a Janus kinase inhibitor, in humans. Drug Metab Dispos. 2014;42(4):759–773. doi:10.1124/dmd.113.054940.
63. B.Y.Chang, F.Zhao, X.He, et al. JAK3 inhibition significantly attenuates psoriasiform skin inflammation in CD18 mutant PL/J mice. J Immunol. 2009;183(3):2183–2192.
64. R.Rückert, K.Asadullah, M.Seifert, et al. Inhibition of keratinocyte apoptosis by IL-15: a new parameter in the pathogenesis of psoriasis? J Immunol. 2000;165(4):2240–2250.
65. B.Strober, M.Buonanno, J.D.Clark, et al. Effect of tofacitinib, a Janus kinase inhibitor, on haematological parameters during 12 weeks of psoriasis treatment. Br J Dermatol. 2013;169(5):992–999. doi:10.1111/bjd.12517.
66. XELJANZ ® (tofacitinib) [package insert]. Pfizer Laboratories Div Pfizer Inc., NY, NY. 2015. Available from: http://labeling.pfizer.com/ShowLabeling.aspx?id=959.
67. K.A.Papp, A.Menter, B.Strober, et al. Efficacy and safety of tofacitinib, an oral Janus kinase inhibitor, in the treatment of psoriasis: a phase 2b randomized placebo-controlled dose-ranging study. Br J Dermatol. 2012;167(3):668–677.•• The first phase II study with published results on oral tofacitinib for the treatment of moderate-to-severe psoriasis.
68. C.Mamolo, J.Harness, H.Tan, et al. Tofacitinib (CP-690,550), an oral Janus kinase inhibitor, improves patient-reported outcomes in a phase 2b, randomized, double-blind, placebo-controlled study in patients with moderate-to-severe psoriasis. J EurAcad Dermatol Venereol. 2014;28(2):192–203.
69. A.G.Bushmakin, C.Mamolo, J.C.Cappelleri, et al. The relationship between pruritus and the clinical signs of psoriasis in patients receiving tofacitinib. J Dermatolog Treat. 2015;26(1):19–22.
70. A.Menter, K.A.Papp, H.Tan, et al. Efficacy of tofacitinib, an oral Janus kinase inhibitor, on clinical signs of moderate-to-severe plaque psoriasis in different body regions. J Drugs Dermatol. 2014;13(3):252–256.
71. F.Valenzuela, K.A.Papp, D.Pariser, et al. Effects of tofacitinib on lymphocyte subpopulations, CMV and EBV viral load in patients with plaque psoriasis. BMC Dermatol. 2015;15:8.
72. H.Bachelez, P.C.M.Van De Kerkhof, R.Strohal, et al. Comparison of tofacitinib versus etanercept or placebo in moderate-to-severe chronic plaque psoriasis: a phase 3 randomized trial. Lancet. 2015;386(9993):552–561.•• Head-to-head phase III study testing tofacitinib versus etanercept for the treatment of moderate-to-severe psoriasis.
73. R.Bissonnette, L.Iversen, H.Sofen, et al. Tofacitinib withdrawal and retreatment in moderate-to-severe chronic plaque psoriasis: a randomized controlled trial. Br J Dermatol. 2015;172(5):1395–1406.
74. K.A.Papp, M.A.Menter, M.Abe, et al. Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: results from two randomized, placebo controlled, phase III trials. Br J Dermatol. 2015;173(4):949–961.•• This phase III clinical trial demonstrates the efficacy of tofacitinib at two doses vs. placebo for moderate-to-severe psoriasis.
75. W.C.Ports, S.Khan, S.Lan, et al. Phase 2a study of topical tofacitinib in chronic plaque psoriasis. Br J Dermatol. 2013;169:137–145.
76. W.C.Ports, S.R.Feldman, P.Gupta, et al. Randomized pilot clinical trial of tofacitinib solution for plaque psoriasis: challenges of the intra-subject study design. J Drugs Dermatol. 2015;14:777–784.
77. V.Di Lernia, F.Bardazzi. Tofacitinib in the treatment of chronic plaque psoriasis. Drug Des Dev Ther. 2016;10:533–539.
78. A.Menter, N.J.Korman, C.A.Elmets, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 4. Guidelines of care for the management and treatment of psoriasis with traditional systemic agents. J Am Acad Dermatol. 2009;61(3):451–485.
79. M.Campa, B.Mansouri, R.Warren, et al. A review of biologic therapies targeting IL-23 and IL-17 for use in moderate-to-severe plaque psoriasis. Dermatol Ther (Heidelb). 2016;6(1):1–12.
80. A.W.Armstrong, A.D.Robertson, J.Wu, et al. Undertreatment, treatment trends, and treatment dissatisfaction among patients with psoriasis and psoriatic arthritis in the United States: findings from the National Psoriasis Foundation surveys, 2003–2011. JAMA Dermatol. 2013;149(10):1180–1185.
81. M.G.Lebwohl, H.Bachelez, J.Barker, et al. Patient perspectives in the management of psoriasis: results from the population-based multinational assessment of psoriasis and psoriatic arthritis survey. J Am Acad Dermatol. 2014;70(5):871–881; e871–830.
82. T.Hanke, D.Merk, D.Steinhilber, et al. Small molecules with anti-inflammatory properties in clinical development. Pharmacol Ther. 2016;157:163–187.
83. T.Tejasvi, P.E.Stuart, V.Chandran, et al. TNFAIP3 gene polymorphisms are associated with response to TNF blockade in psoriasis. J Invest Dermatol. 2012;132:593–600.
84. Y.Vasilopoulos, M.Manolika, E.Zafiriou, et al. Pharmacogenetic analysis of TNF, TNFRSF1A, and TNFRSF1B gene polymorphisms and prediction of response to anti-TNF therapy in psoriasis patients in the Greek population. Mol Diagn Ther. 2012;16:29–34.
85. M.Talamonti, E.Botti, M.Galluzzo, et al. Pharmacogenetics of psoriasis: HLA-Cw6 but not LCE3B/3C deletion nor TNFAIP3 polymorphism predisposes to clinical response to interleukin 12/23 blocker ustekinumab. Br J Dermatol. 2013;169:458–463.
86. M.Talamonti, M.Galluzzo, S.Chimenti, et al. HLA-C*06 and response to ustekinumab in Caucasian patients with psoriasis: outcome and long-term follow-up. J Am Acad Dermatol. 2016;74(2):374–375.
87. M.Galluzzo, A.N.Boca, E.Botti, et al. IL12B (p40) gene polymorphisms contribute to ustekinumab response prediction in psoriasis. Dermatology. 2016;232(2):230–236.
88. E.Herédi, A.Csordás, M.Clemens, et al. The prevalence of obesity is increased in patients with late compared with early onset psoriasis. Ann Epidemiol. 2013;23(11):688–689.
89. S.Bremmer, A.S.Van Voorhees, S.Hsu, et al. Obesity and psoriasis: from the Medical Board of the National Psoriasis Foundation. J Am Acad Dermatol. 2010;63:1058–1069.
90. B.Engin, Z.Kutlubay, G.Yardimci, et al. Evaluation of body composition parameters in patients with psoriasis. Int J Dermatol. 2014;53:1468–1473.
91. M.D.Herron, M.Hinckley, M.S.Hoffman, et al. The impact of obesity and smoking on psoriasis presentation and management. Arch Dermatol. 2005;141:1527–1534.
92. L.Mallbris, F.Granath, A.Hamstem, et al. Psoriasis is associated with lipid abnormalities at the onset of skin disease. J Am Acad Dermatol. 2006;54:614–621.
93. S.Coimbra, H.Oliveira, F.Reis, et al. C-reactive protein and leucocyte activation in psoriasis vulgaris according to severity and therapy. J Eur Acad Dermatol Venereol. 2010;24:789–796.
94. C.Charles-Schoeman, R.Fleischmann, J.Davignon, et al. Potential mechanisms leading to the abnormal lipid profile in patients with rheumatoid arthritis versus healthy volunteers and reversal by tofacitinib. Arthritis Rheumatol. 2015;67(3):616–625.
95. A.A.Van Der Lans, J.Hoeks, B.Brans, et al. Cold acclimation recruits human brown fat and increases nonshivering thermogenesis. J Clin Investig. 2013;123:3395–3403.
96. T.Yoneshiro, S.Aita, M.Matsushita, et al. Recruited brown adipose tissue as an antiobesity agent in humans. J Clin Investig. 2013;123:3404–3408.
97. A.Moisan, Y.K.Lee, J.D.Zhang, et al. White-to-brown metabolic conversion of human adipocytes by JAK inhibition. Nat Cell Biol. 2015;17(1):57–67.
98. A.Bartelt, O.T.Bruns, R.Reimer, et al. Brown adipose tissue activity controls triglyceride clearance. Nat Med. 2011;17:200–205.
99. K.I.Stanford, R.J.Middelbeek, K.L.Townsend, et al. Brown adipose tissue regulates glucose homeostasis and insulin sensitivity. J Clin Investig. 2013;123:215–223.
100. A.M.Cypess, S.Lehman, G.Williams, et al. Identification and importance of brown adipose tissue in adult humans. N Engl J Med. 2009;360:1509–1517.